Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
SPECIAL ANNOUNCEMENT
2016 Photonics Buyers' Guide Clearance! – Use Coupon Code FC16 to save 60%!
share
Email Facebook Twitter Google+ LinkedIn Comments

Patent Application Filed for MOR103 Program

Photonics Spectra
Aug 2009
MorphoSys AG of Martinsried, Germany, and Melbourne Ventures Pty. Ltd., a wholly owned commercial subsidiary of the University of Melbourne in Australia, have formed a joint venture in the investigation of the therapeutic applications of MorphoSys’ MOR103 program, a HuCAL (Human Combinatorial Antibody Library) antibody against human GM-CSF (granulocyte macrophage-colony stimulating factor) being developed for the treatment of rheumatoid arthritis. MorphoSys also has been issued patent No. 4,312,403 from the Japanese Patent Office for its CysDisplay, a component of the HuCAL platform. The patent, titled “Novel Methods for Displaying (Poly) Peptides/Proteins on Bacteriophage Particles,” describes a technology-based phage display screening system for selecting high-affinity antibodies.


Comments
Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2016 Photonics Media
x Subscribe to Photonics Spectra magazine - FREE!